clinical trial · NCT06881251
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
Janssen Research & Development, LLC·phase2·terminated·n = 256
Dermatitis, AtopicDupilumabJNJ-95475939Placebo
brief summary
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
started
Feb 26, 2025
primary completion
Mar 26, 2026
completion
Apr 7, 2026
last updated
Jun 4, 2026
official title
95475939ADM2001: 95475939ADM2001 Ph IIB Trial (N=210)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol